© 1996 by Oxford University Press
Journal of the National Cancer Institute, Vol. 88, No. 23, 1764-1769,
December 4, 1996
© 1996 Oxford University Press
Angiogenesis as a Predictor of Long-term Survival for Patients With Node-Negative Breast Cancer
Department of Radiation and Cellular Oncology, Division of the Biological Sciences, The Pritzker School of Medicine, The University of Chicago IL
Department of Surgery, Division of the Biological Sciences, The Pritzker School of Medicine, The University of Chicago IL
Department of Pathology, Division of the Biological Sciences, The Pritzker School of Medicine, The University of Chicago IL
Correspondence to: Ruth Heimann, M.D., Ph.D., Department of Radiation and Cellular Oncology, The University of Chicago, UC 0085, 5841 S. Maryland Ave., Chicago, IL 60637
BACKGROUND: Angiogenesis (the formation of new blood vessels) is necessary for tumor growth and metastasis.
PURPOSE: We investigated whether angiogenesis as measured by microvessel count (MVC) predicts clinical outcome in a series of patients with axillary lymph node-negative breast cancer who received no adjuvant therapy and who were followed for a long period of time. Our long-term goal is to identify those patients who may or may not need adjuvant chemotherapy.
METHODS: Pathologic archival material and clinical information were analyzed for 167 patients treated with mastectomy from 1941 through 1987; none received adjuvant treatment The median follow-up time among living patients was 15.4 years (range, 2.6–35.8 years). Ninety-six (58%) patients had a tumor size of 2 cm or less, 52 (31 %) had tumors of 2.1–3 cm, and 19 (11%) had tumors of larger than 3 cm. Paraffin-embedded tissue sections were stained for expression of CD34 antigen on microves-sel-associated endothelial cells by use of a monoclonal anti-CD34 antibody. Vascularity was defined as the number of microvessels (average of the three highest counts) per high-power microscopic field (400x magnification) in the area of highest vascular density. A high vascular count was defined as 15 or more microvessels per field. Actuarial survival curves were calculated according to the Kaplan-Meier method and comparisons were made with the logrank test. The Cox proportional hazards model was used for multivariate analysis. AD P values were based on two-sided testing.
RESULTS: The 20-year disease-free survival (DFS) for the 167 node-negative patients treated with mastectomy and no adjuvant therapy was 74.8% (95% confidence interval [CI] = 64.7%–82.0%). The 20-year DFS was 93.1% (95% CI = 79.9%–97.7%) if the MVC was low versus 68.9% (95% CI = 56.8%-78.0%) if the MVC was high (P = .018). This difference was maintained irrespective of tumor size: for tumor size of 2 an or less (93.3% [95% CI = 753%–983%] versus 67.8% [95% CI = 50.1%–803%]) and for tumor size of larger than 2 cm (92.3% [95% CI = 56.6%–98.9%] versus 70.9% [95% CI = 54.6%–81.6%]). However, the likelihood of a high MVC was greater with large tumors (P = .05). The proportions of tumors with low and high MVC were 33% and 67%, respectively, if the tumor size was 2 cm or less, and 20% and 80%, respectively, if tumor size was larger than 2 an. There was no significant difference in the 20-year DFS as a function of tumor grade (P = .2). After combining patients with tumors of nuclear grades 2 and 3 compared with those of nuclear grade 1, the 20-year DFS was 93.9% (95% CI = 77J%–98.4%) for low MVC versus 66.9% (95% CI = 52.2%–78.0%) for high MVC (P = .02). In a multivariate analysis that included the variables tumor size, age, nuclear grade, estrogen receptor status, and MVC, only MVC appeared to be an independent prognostic indicator (P = .04).
CONCLUSIONS: Angiogenesis as measured by MVC is a reliable independent prognostic marker of long-term survival in patients with node-negative breast cancer. The prognostic usefulness of this marker is maintained after more than 15 years of follow-up. A low MVC identifies a subgroup of patients with DFS of 92% or more, independent of tumor size or grade. [J Natl Cancer Inst 1996;88: 1764–9]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  I. Benakanakere, C. Besch-Williford, J. Schnell, S. Brandt, M. R. Ellersieck, A. Molinolo, and S. M. Hyder Natural and Synthetic Progestins Accelerate 7,12-Dimethylbenz[a]Anthracene-Initiated Mammary Tumors and Increase Angiogenesis in Sprague-Dawley Rats. Clin. Cancer Res., July 1, 2006; 12(13): 4062 - 4071. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Yabu, H. Tomimoto, Y. Taguchi, S. Yamaoka, Y. Igarashi, and T. Okazaki Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1-phosphate Blood, July 1, 2005; 106(1): 125 - 134. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Wu, R. Burghardt, and S. Safe Vitamin D-interacting Protein 205 (DRIP205) Coactivation of Estrogen Receptor {alpha} (ER{alpha}) Involves Multiple Domains of Both Proteins J. Biol. Chem., December 17, 2004; 279(51): 53602 - 53612. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Uzzan, P. Nicolas, M. Cucherat, and G.-Y. Perret Microvessel Density as a Prognostic Factor in Women with Breast Cancer: A Systematic Review of the Literature and Meta-Analysis Cancer Res., May 1, 2004; 64(9): 2941 - 2955. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Wulfing, C. Kersting, J. Tio, R.-J. Fischer, C. Wulfing, C. Poremba, R. Diallo, W. Bocker, and L. Kiesel Endothelin-1-, Endothelin-A-, and Endothelin-B-Receptor Expression Is Correlated with Vascular Endothelial Growth Factor Expression and Angiogenesis in Breast Cancer Clin. Cancer Res., April 1, 2004; 10(7): 2393 - 2400. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N B Teo, B S Shoker, C Jarvis, J P Sloane, and C Holcombe Thymidine phosphorylase expression and stromal vascularity in ductal carcinoma in situ of the breast J. Clin. Pathol., December 1, 2003; 56(12): 919 - 923. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Liu, L. H. Cheung, P. Thorpe, and M. G. Rosenblum Mechanistic studies of a novel human fusion toxin composed of vascular endothelial growth factor (VEGF)121 and the serine protease granzyme B: Directed apoptotic events in vascular endothelial cells Mol. Cancer Ther., October 1, 2003; 2(10): 949 - 959. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. C. Voogd, M. Nielsen, J. L. Peterse, M. Blichert-Toft, H. Bartelink, M. Overgaard, G. van Tienhoven, K. W. Andersen, R. J. Sylvester, and J. A. van Dongen Differences in Risk Factors for Local and Distant Recurrence After Breast-Conserving Therapy or Mastectomy for Stage I and II Breast Cancer: Pooled Results of Two Large European Randomized Trials J. Clin. Oncol., March 15, 2001; 19(6): 1688 - 1697. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. T.-P. Poon, S.-T. Fan, and J. Wong Clinical Implications of Circulating Angiogenic Factors in Cancer Patients J. Clin. Oncol., February 15, 2001; 19(4): 1207 - 1225. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Adams, P. J. Carder, S. Downey, M. A. Forbes, K. MacLennan, V. Allgar, S. Kaufman, S. Hallam, R. Bicknell, J. J. Walker, et al. Vascular Endothelial Growth Factor (VEGF) in Breast Cancer: Comparison of Plasma, Serum, and Tissue VEGF and Microvessel Density and Effects of Tamoxifen Cancer Res., June 1, 2000; 60(11): 2898 - 2905. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Heimann and S. Hellman Clinical Progression of Breast Cancer Malignant Behavior: What to Expect and When to Expect it J. Clin. Oncol., February 1, 2000; 18(3): 591 - 591. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Heimann, F. Lan, R. McBride, and S. Hellman Separating Favorable from Unfavorable Prognostic Markers in Breast Cancer: The Role of E-Cadherin Cancer Res., January 1, 2000; 60(2): 298 - 304. [Abstract] [Full Text]
|
|
|
|
|
|
S. D. Placido, C. Carlomagno, F. Ciardiello, M. D. Laurentiis, S. Pepe, A. Ruggiero, G. Tortora, L. Panico, A. D'Antonio, G. Pettinato, et al. Measurement of Neovascularization Is an Independent Prognosticator of Survival in Node-negative Breast Cancer Patients with Long-Term Follow-Up Clin. Cancer Res., October 1, 1999; 5(10): 2854 - 2859. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. G. Karrison, D. J. Ferguson, and P. Meier Dormancy of Mammary Carcinoma After Mastectomy J Natl Cancer Inst, January 6, 1999; 91(1): 80 - 85. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Montrucchio, A. Sapino, B. Bussolati, G. Ghisolfi, S. Rizea-Savu, L. Silvestro, E. Lupia, and G. Camussi Potential Angiogenic Role of Platelet-Activating Factor in Human Breast Cancer Am. J. Pathol., November 1, 1998; 153(5): 1589 - 1596. [Abstract] [Full Text] [PDF]
|
|